Strides Pharma Science Ltd · NSE:STAR
Strides Pharma Science — Q2 FY2022 Earnings Presentation
23 slides from Strides Pharma Science's earnings presentation, Nov 10, 2021
Slide 1: Q2 and H1FY22 Earnings
Q2 and H1FY22 Earnings November 10, 2021
Slide 2: Strides reports muted Q2FY22 results
Strides reports muted Q2FY22 results Successfully completes acquisition of Chestnut Ridge site along with ANDA’s from Endo We have reported an operational breakeven in Q2FY22 enabled by a bounce Revenues Mix back in other regulated markets, growing 27% QoQ. The performance in other regulated markets
Slide 3: Financial performance in Q2 and H1 FY22
Financial performance in Q2 and H1 FY22 Q2FY22 Q1FY22 Q2FY21 QoQ% YoY% H1FY22 H1FY21 YoY % REVENUES ₹7,360m ₹6,919m ₹7,971m 6% - 8% ₹14,279m ₹15,818m - 10% ₹4,113m ₹3,428m ₹4,886m 20% - 16% ₹7,541m ₹9,711m - 22% GROSS MARGINS 55.9% 49.5% 61.3% 630 bps - 540 bps 52.8% 61.4% - 860 bps ₹10m - ₹468m ₹1,
Slide 4: Performance Overview
Performance Overview Key Updates Regulated Markets Regulated Markets US Market Q2FY22 Q1FY22 Q2FY21 QoQ% YoY% H1FY22 H1FY21 YoY% • US revenues at $34m for Q2FY22, US contributed 34% of consolidated revenues in Q2FY22 • Demand continued to be impacted by Covid-19 related headwinds US 2,502 3,016 4,04
Slide 5: Business Highlights
Business Highlights
Slide 6: US business continued to witness headwinds, growth to resume starting Q3FY22
US business continued to witness headwinds, growth to resume starting Q3FY22 US Revenues - Quarterly Trend (₹/$M) Business Updates Significant price • Revenues from the US for Q2FY22 stood at ₹2,502 ($34m), down 38% YoY, erosion impacts representing 34% of consolidated revenues for Q2FY22 $53 $58 $5
Slide 7: Chestnut Ridge transaction achieves completion
Chestnut Ridge transaction achieves completion Transaction Update Strategic Outcomes Key Priorities • Acquisition strengthens Strides’ portfolio, front-end presence and local manufacturing capability for the US • The acquisition more than doubles the approved ANDA • Strides welcomes on board the exp
Slide 8: Robust portfolio in place to drive growth for the US business
Robust portfolio in place to drive growth for the US business Addressable Strides Endo Combined Dosage Format Market Size Portfolio Portfolio Portfolio US$ m Portfolio Highlights • Combined portfolio of 273 ANDA’s spread across multiple dosage Oral Solids ER 12 12 24 2,717 format • Acquired portfoli
Slide 9: Bounce back in the other regulated markets with growth across key markets
Bounce back in the other regulated markets with growth across key markets Other Regulated Markets Revenues - Quarterly Trend (₹/$M) Business Updates Covid related supply • Revenues from other regulated markets for Q2FY22 stood at ₹2,825m $40 disruptions ($38m), up 27% QoQ and 18% YoY $37 $38 $35 $31
Slide 10: Emerging markets business continues its growth momentum with a 32% YoY growth
Emerging markets business continues its growth momentum with a 32% YoY growth Emerging Market Revenues - Quarterly Trend (₹/$M) Business Updates • Revenues from emerging markets for Q2FY22 stood at ₹2,033m ($28m), up 22% QoQ and up 32% YoY $29 $28 $23 • Emerging markets business represented 28% of c
Slide 11: Financial Performance
Financial Performance
Slide 12: Key P&L Highlights – Q2 and H1FY22
Key P&L Highlights – Q2 and H1FY22 Income statement (₹m) Particulars Q2 FY22 Q1 FY22 Q2 FY21 QoQ YoY H1 FY22 H1 FY21 YoY Revenues 7,360 6,919 7,971 6% -8% 14,279 15,818 -10% EBITDA 10 -468 1,656 101% -100% -458 3,234 -114% EBITDA % 0.1% -6.8% 20.8% 690 bps -2070 bps -3.2% 20.4% Adj PAT1 -847 -1,169
Slide 13: Net debt and Investments
Net debt and Investments Pharma Net Debt Investments in CHC & Biotech Total Net Debt As at June 2021 As at June 2021 As at June 2021 ₹ 7,530m ₹ 6,886m ₹ 14,416m As at September 2021 As at September 2021 As at September 2021 ₹ 9,301m ₹ 6,937m ₹ 16,238m Change over June 2021 Change over June 2021 Chan
Slide 14: Q2 and H1FY22 Earnings Call invitation
Strides Pharma Science Ltd – Q2 and H1FY22 Earnings Call Pre-register and join without operator CLICK HERE invites you to interact with the senior management on Q2 and H1FY22 Join through an operator using dial in WEDNESDAY, NOVEMBER 10, 2021 numbers 4:00pm IST / 11:30am BST / 06:30am EDT / 06:30pm
Slide 15: Thank You
Thank You Strides Pharma Science Limited CIN: L24230MH1990PLC057062 CORPORATE OFFICE 201, Devavrata, Sector 17, Vashi, Navi Mumbai - 400 703, India Tel.: +91 22 2789 2924/2789 3199 Email: corpcomm@strides.com Website: www.strides.com CIN: L24230MH1990PLC057062 REGISTERED OFFICE Bannerghatta Road, Be
Slide 16: An integrated biologics and vaccine player in the making
An integrated biologics and vaccine player in the making Stelis Biopharma Limited | November 10, 2021
Slide 17: Recap: Stelis is a vertically integrated biopharma and vaccine company ready to expand horizons
z Recap: Stelis is a vertically integrated biopharma and vaccine company ready to expand horizons Large Scale Infrastructure One Stop Capabilities Integrated vaccine suite ▸ 3 World class facilities with ▸ One-stop shop solution from cell ▸ Dedicated vaccine facility to cater ~600,000 Square feet R&
Slide 18: Updates on Q2FY22 Performance
Updates on Q2FY22 Performance 3 operating businesses are tracking to the plan albeit delayed facility inspections due to travel restrictions
Slide 19: The CDMO business is on track to achieve operational break even in FY22
z The CDMO business is on track to achieve operational break even in FY22 • New orders received for the drug product facility, continued traction for cartridges, high speed vial fill-finish and lyophilized vials Current Business and Orderbook • Completed large scale batches(1000L) for microbial drug
Slide 20: Since the outbreak of Covid-19, Stelis has expanded its scope to manufacture vaccines at large scale
z Since the outbreak of Covid-19, Stelis has expanded its scope to manufacture vaccines at large scale Update on Sputnik Vaccine In its commitment to fight against Covid-19, Stelis rose to the challenge and planned its foray into vaccines in March 2021 • First component of the Sputnik vaccine has be
Slide 21: In <180 days, our team is ready to produce 720 million vaccine shots per year
IN <180 DAYS, OUR TEAM IS READY TO PRODUCE 720 MILLION VACCINE SHOTS PER YEAR AND CAN EXPAND TO 1 BILLION ANNUAL DOSES CAPACITY
Slide 22: Our biosimilar products are tracking to plan with first insulin analog completing India CT trials
z Our biosimilar products are tracking to plan with first insulin analog completing India CT trials Development Molecule Market Size ($b) Indication Latest Update Stage Filed in EU/ STLP001 • EU file for MAA under review, on track to received approval by ~2 Osteoporosis Phase 1 ready for (Rh- Teripa
Slide 23: Thank you
Thank you For details, please visit www.stelisbiosource.com Stelis Biopharma Limited (Formerly Stelis Biopharma Private Limited) tar 1 Building, Opp. IIM Bangalore, Bilekahalli, Banngerghatta Road, Bangalore – 560 076, India Tel: +91 80 6784 0738 CIN: U74140KA2007PLC043095 For business and investor
Strides Pharma Science — Q2 FY2022 Earnings Presentation on 6ix